ArticleIranian journal of basic medical sciences2026
Down-regulation of AGXT2L1 promotes the development of nonalcoholic fatty liver disease.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the role of alanine-glyoxylate aminotransferase 2-like1 (AGXT2L1) in Nonalcoholic fatty liver disease (NAFLD) and its underlying mechanisms. Materials and Methods: Changes in AGXT2L1 expression during NASH progression were analyzed using tissue samples, cell experiments, and animal models. RNA sequencing was performed on experimental mice to explore potential mechanisms by assessing inflammatory factors, cell apoptosis, and endoplasmic reticulum stress. Results: Compared with normal tissues, AGXT2L1 expression was reduced in multiple liver diseases. Both Conclusion: Decreased AGXT2L1 expression is an evident alteration in liver injury. It has been indicated that down-regulation of AGXT2L1 promotes NAFLD development, possibly through three pathways: activation of inflammatory responses, promotion of hepatocyte apoptosis, and enhancement of endoplasmic reticulum stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.